The Dermatology Digest

MARCH 17, 2025

has enrolled of the first patient in a Phase 2 trial of EVO301, an injectable interleukin (IL)-18 neutralizer, in moderate-to-severe atopic dermatitis (AD). EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis. Evommune, Inc.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

Dermatology Times

AUGUST 27, 2024

The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.

Dermatitis 45

Dermatitis Treatments Therapy 45

Dermatology Times

MARCH 10, 2025

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Dermatitis 53

Dermatitis Therapy Safety Treatments 53

The Dermatology Digest

DECEMBER 11, 2024

pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA )agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. The most common (>5%) AEs observed were nasopharyngitis, atopic dermatitis and headache. AnaptysBio, Inc.is

Safety 36

Safety Dermatitis Therapy Dermatology 36

Dermatology Times

MARCH 14, 2025

Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

First Derm

JUNE 10, 2024

Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.

Dermatitis 45

Dermatitis Irritation Eczema Dry Skin 45

Dermatology Times

DECEMBER 24, 2024

James Song, MD, FAAD, discusses how recent advancements in atopic dermatitis treatment include targeted biologics and Janus kinase inhibitors that offer promising alternatives to traditional therapies for patients with moderate-to-severe disease.

Dermatitis 36

Dermatitis Therapy Treatments 36

The Dermatology Digest

JANUARY 13, 2025

Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Dermatology Digest

FEBRUARY 18, 2025

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN. Food and Drug Administration for the treatment of AD and PN.

Dermatitis 36

Dermatitis Marketing Hospital Clinic 36

First Derm

FEBRUARY 21, 2024

Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?

Eczema 59

Eczema Dermatitis Management Medical 59

Dermatology Times

DECEMBER 31, 2024

A panelist discusses how precision medicine enables targeted atopic dermatitis treatments by matching specific therapies to patients based on their unique disease characteristics and biomarkers

Dermatitis 36

Dermatitis Treatments Therapy 36

The Dermatology Digest

APRIL 1, 2025

We have seen immense therapeutic innovation in the treatment of AD, PN, and chronic CSU, over the past decade, the reviews first author Raj Chovatiya, MD, PhD, MSCI,Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago,tells The Dermatology Digest. Dover says.

Dermatitis 36

Dermatitis Dermatology Therapy Tools 36

Dermatology Times

FEBRUARY 28, 2025

Panelists discuss how clinicians can evaluate the severity of atopic dermatitis through comprehensive assessment of symptoms, quality-of-life impact, and treatment response to guide decisions about transitioning patients to systemic therapy.

Dermatitis 36

Dermatitis Therapy Treatments 36

Dermatology Times

DECEMBER 4, 2024

Gina Mangin, MPAS, PA-C, discusses how developing an effective atopic dermatitis treatment plan requires a personalized, multifaceted approach that combines proper skin care, trigger avoidance, topical medications, and potentially systemic therapies based on the severity of symptoms and individual patient needs.

Dermatitis 36

Dermatitis Treatments Therapy Medical 36

Dermatology Times

DECEMBER 24, 2024

James Song, MD, FAAD, discusses how improving patient adherence to atopic dermatitis treatments requires addressing barriers such as cost, treatment complexity, and patient education, while highlighting how emerging therapies and simplified regimens may help overcome these challenges in the future.

Dermatitis 36

Dermatitis Treatments Education Therapy 36

Dermatology Times

MAY 30, 2024

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative. (..)

Dermatitis 72

Dermatitis Therapy Management Treatments 72

Dermatology Times

AUGUST 9, 2024

Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.

Dermatitis 41

Dermatitis Treatments Therapy 41

The Dermatology Digest

FEBRUARY 10, 2025

Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. “We are pleased that rezpegaldesleukin has been designated a Fast Track product,” says Jonathan Zalevsky, Ph.D.,

Dermatitis 36

Dermatitis Therapy Office Safety 36

Dermatology Times

FEBRUARY 18, 2025

Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.

Dermatology 68

Dermatology Dermatitis Therapy Treatments 68

Dermatology Times

MARCH 6, 2025

The panelist discusses how to evaluate the need for and manage the transition between biologic therapies in a 32-year-old woman with severe atopic dermatitis who has had an inadequate response to initial treatment.

Dermatitis 36

Dermatitis Therapy Management Treatments 36

Dermatology Times

APRIL 11, 2025

Jennifer Soung, MD, discusses how pediatric atopic dermatitis (AD) burdens entire families through sleep disruption and emotional toll. Parents seek effective nonsteroidal options beyond current treatments. Convenient topical Janus kinase (JAK) inhibitors could improve adherence and outcomes.

Dermatitis 36

Dermatitis Therapy Treatments 36

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

Dermatology Times

FEBRUARY 17, 2025

The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

Dermatology Times

MARCH 28, 2025

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

Dermatitis 36

Dermatitis Safety Education Therapy 36

Dermatology Times

JUNE 20, 2024

Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation (..)

Dermatitis 36

Dermatitis Treatments Therapy Management 36

Dermatology Times

DECEMBER 10, 2024

Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.

Dermatitis 36

Dermatitis Clinic Therapy Management 36

Dermatology Times

MARCH 7, 2025

Panelists discuss how clinicians can choose the most appropriate systemic treatment for moderate to severe atopic dermatitis by evaluating patient characteristics, comorbidities, and therapeutic goals while considering the latest clinical evidence.

Dermatitis 36

Dermatitis Therapy Clinic Treatments 36

Dermatology Times

FEBRUARY 27, 2025

The panelist discusses how to optimize topical therapy selection and application strategies for a young man with mild atopic dermatitis to achieve symptom control and maintain skin barrier function.

Dermatitis 36

Dermatitis Therapy Treatments 36

Dermatology Times

MARCH 3, 2025

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.

Dermatitis 36

Dermatitis Therapy Safety Treatments 36

Dermatology Times

FEBRUARY 11, 2025

A recent expert discussion highlighted the importance of long-term planning, including when and how to adjust or transition therapies.

Education 41

Education Dermatitis Treatments Therapy 41

First Derm

FEBRUARY 6, 2024

Online Dermatologist Topical Steroid Withdrawal: Causes, Symptoms, and Treatments What is Topical Steroid Withdrawal? Professional Guidance is Essential : Consulting healthcare professionals is vital for obtaining an accurate diagnosis, understanding your condition, and developing a personalized treatment plan. Dermatitis.

Treatments 59

Treatments Dermatitis Management Skin Issues 59

Dermatology Times

FEBRUARY 24, 2025

The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.

Dermatitis 36

Dermatitis Safety Therapy Management 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Dermatology Times

FEBRUARY 28, 2025

Panelists discuss how physicians can achieve optimal atopic dermatitis management by following American Academy of Dermatology (AAD) guidelines for systemic therapy selection while considering individual patient factors and treatment goals.

Therapy 36

Therapy Dermatitis Management Dermatology 36

Dermatology Times

SEPTEMBER 20, 2023

Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.

Therapy 41

Therapy Dermatitis Treatments 41

Dermatology Times

MARCH 29, 2024

Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.

Therapy 36

Therapy Dermatitis Treatments 36